An Early Phase 1 interventional study of Biolimus A9 Drug Coated Balloon and SELUTION SLR in Angina (Stable), Unstable Angina (UA) and NSTEMI, sponsored by Biosensors Europe SA. Not yet recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Biosensors Europe SA (part of Blue Sail Medical Co., Ltd.) · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Angina, Stable with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Angina, Stable · United Kingdom.
Among the 47 studies in Angina, Stable with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 1, reaches primary completion later than 9 of the 12 other live ones, and was the 47th registered.
344 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.
Browse Angina, Stable studies →9 of the 47 studies in Angina, Stable with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen Mary University of London · Sites in United Kingdom
Ages 18–79
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 39 Angina, Stable studies recruiting now, 33 (85%) set no upper age limit and 2 (5%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 443 is above the median of 150 across 230 interventional studies indexed under Angina, Stable.
Median enrollment 240 across the 26 interventional studies, 20,000 across the 21 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biosensors Europe SA, one of the names counted as Blue Sail Medical Co., Ltd.. Under that name alone:
Biosensors Europe SA is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Blue Sail Medical Co., Ltd. has 6 studies filed under Angina, Stable — fewer than ten, so there is no comparison to draw.
2 of the studies in Angina, Stable with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06400290Imperial College LondonMultivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina | 2027-01 |
| NCT06854302NHS National Waiting Times Centre BoardAngina After PCI: a Systems Medicine Study | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 47 studies in Angina, Stable with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle.
One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal.
Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed.
In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe.
The study has the following design:
The study has the following design:
Devices used :
Investigational device: BioRISE Biolimus Drug-Coated Balloon. Comparator: SELUTION SLR sirolimus-coated balloon (de novo randomised cohort only).
Purpose and Background:
Coronary drug-coated balloons provide an anti-restenotic effect without a permanent implant. This study evaluates the BioRISE Biolimus Drug-Coated Balloon against an established sirolimus drug-eluting balloon (SELUTION SLR) in de novo coronary lesions, with a supportive single-arm cohort in in-stent restenosis, to generate clinical evidence supporting CE marking under Regulation (EU) 2017/745 (MDR).
Clinical Development stage:
Pre-Market Phase (Interventional) - Pivotal clinical investigation.
Study population:
Patients with de novo coronary artery lesions (randomised cohort) and with in-stent restenosis (single-arm cohort).
Total 443 subjects: 400 randomised de novo (200 BioRISE : 200 SELUTION SLR) plus 43 ISR (BioRISE only), at up to 25 sites in up to 6 European countries.
Design:
Prospective, randomised (1:1), multicentre, single-blind (with blinded angiographic core laboratory and blinded independent CEC adjudication study with an additional single-arm ISR safety cohort.
Objectives:
Demonstrate non-inferiority of BioRISE versus SELUTION SLR for in-segment LLL at 9 months in de novo coronary lesions.
Primary endpoints:
In-segment Late Lumen Loss (LLL) (or Gain) at 9 months Defined as the difference between post-procedural minimal lumen diameter (MLD) and 9-month follow-up MLD, measured by quantitative coronary angiography (QCA), assessed by a blinded angiographic core laboratory.
Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.
Primary Endpoint Justification:
Per ARC-DCB, LLL is expected to be reliable when comparing different types of DCBs (DCB vs DCB).
Clinical secondary endpoints
Lesion-Oriented Composite Endpoint (LOCE; ARC-DCB) at 30 days: definite lesion thrombosis, clinically driven TLR, and device-failure-related MI (not clearly attributable to a non-target vessel).
Target Lesion Failure (TLF; ARC-DCB) at all timepoints: composite of cardiovascular death, target-vessel MI, and clinically driven TLR.
Target Vessel Failure (TVF; ARC-DCB) at all timepoints: cardiovascular death, target-vessel MI, and clinically driven target vessel revascularisation.
Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction).
Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints
Any definite lesion thrombosis (ARC-DCB [20]): angiographic confirmation of thrombus originating in, or within 5 mm of, the treated segment, or pathological (autopsy) confirmation, in the presence of an acute ischaemic clinical syndrome. Classified by timing as acute (≤ 24 h), subacute (> 24 h-30 days), late (> 30 days-1 year) and very late (> 1 year).
All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC [34], as adopted by ARC-DCB) at discharge, 30 days and 1 year
Binary restenosis (> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB).
Device success (ARC-DCB): successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use), successful withdrawal of the device system, and attainment of a final in-segment residual stenosis of \<40% with final data reported by core laboratory QCA.
Procedural success (ARC-DCB): device success and freedom from in-hospital cardiovascular death, TLR, peri-procedural MI, any stroke and BARC 3-5 bleeding.
OCT substudy:
Pre-specified OCT sub-study at participating sites (de novo cohort only) in UK, restricted to subjects whose target lesion has a reference vessel diameter (RVD) ≥ 3.0 mm by visual estimation. In 30 subjects (15 per randomised arm), OCT of the target lesion is acquired at two time points: after lesion preparation (before randomisation and DCB application) and at the 9-month angiographic follow-up and analysed at 1 mm intervals of the treated segment by the OCT core laboratory (CERC).
The primary OCT outcome measure is the percentage change in minimal lumen area from post-lesion preparation to 9 months, compared between BioRISE and SELUTION SLR in 15 subjects per randomised arm (30% lumen-area reduction assumed in both arms, 50% non-inferiority limit, α = 5%, 90% power).
Additional variables include plaque characterisation and dissection after lesion preparation, plaque healing/layering at 9 months and treated-segment lumen volume.
Sub-study analyses are exploratory and do not contribute to the confirmatory analysis of the primary endpoint.
Randomization:
1:1 (BioRISE : SELUTION SLR) via a central, validated electronic randomisation system in the EDC, with concealed allocation, using randomly permuted blocks of variable size, stratified by site. Randomisation is performed after successful lesion preparation (Inclusion Criterion 15) and immediately before device application. The single-arm ISR cohort is not randomised.
Study oversight:
An independent DSMB reviews safety data at pre-specified intervals per the DSMB Charter. An independent Clinical Events Committee (CEC) adjudicates deaths, MI, stroke, lesion thrombosis and revascularisations.
An angiographic core laboratory (CERC) performs QCA/QFR. The study is monitored per a monitoring plan, with data captured in a validated electronic data capture (EDC) system.
Follow-up:
Discharge; 30 days (± 7 days); 9 months (± 30 days, with protocol-mandated coronary angiography - primary endpoint); and 1, 2 and 3 years (± 30 days). Visits are performed in clinic as specified in the follow-up schedule.
Study duration:
Approximately 12 months enrollment; each subject is followed for approximately 3 years. The primary-endpoint analysis is performed after all subjects complete the 9-month angiographic follow-up.
Statistical considerations:
De novo cohort:
Non-inferiority of BioRISE versus SELUTION SLR on in-segment LLL at 9 months. With a margin Δ = 0.19 mm, common SD 0.50 mm, at least 90% power and α = 5% two-sided (2.5% one-sided), 178 evaluable subjects per arm are required; allowing for 11% drop-out, 400 subjects are randomised (200 : 200).
Primary analysis per-protocol with supplementary ITT; non-inferiority is concluded if the upper bound of the two-sided 95% CI for the mean LLL difference (BioRISE - SELUTION SLR) is \< 0.19 mm.
If met, superiority is subsequently tested.
ISR cohort:
Single-arm, descriptive; in-segment LLL at 9 months against a performance goal of 0.497 mm (sirolimus arm of SIBLINT and Biolimus arm of BIO-ASCEND ISR; weighted late loss 0.297 mm, weighted SD 0.427 mm). With a margin Δ = 0.2 mm, 80% power and α = 2.5% one-sided, 38 evaluable subjects are required; allowing for 10% drop-out, 43 are enrolled.
Total study enrollment: 443 subjects.
OCT sub-study (de novo cohort): percentage change in MLA from post-lesion preparation to 9 months, 30% expected in both arms, 50% non-inferiority limit, 90% power: 15 subjects per randomised arm (30 in total).
GCP statement and ISO:14155: 2026 This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, ISO 14155:2026 as well as all national legal, MDR and regulatory requirements.
Inclusion Criteria:
Age ≥ 18 years
Exclusion Criteria:
General (all patients):
All target lesions: baseline diameter stenosis > 50% and \< 100% with distal flow of at least TIMI 2. For angiographically intermediate lesions where the indication for PCI is uncertain, lesion-specific evidence of ischaemia is demonstrated by an accepted physiological assessment (e.g. FFR, iFR or validated angiography-derived physiology) at baseline.
De Novo Cohort (Randomised):
Successful lesion predilatation/preparation prior to study DCB delivery: TIMI 3 flow, residual diameter stenosis \< 30%, and no flow-limiting or vessel-threatening dissection requiring further treatment or bail-out stenting.
ISR Cohort (Single-Arm, BioRISE only):
Exclusion criteria:
General all patients:
Subject is under judicial protection, tutorship or curatorship (France only, if selected).
De Novo Cohort (Randomised) - additional:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BioRISE is a semi-compliant, rapid-exchange (RX) percutaneous transluminal coronary angioplasty (PTCA) balloon catheter built on the CE-marked RISE™ SC catheter platform with modified hypotube, compatible with a 0.014" guidewire. The device leaves no permanent implant, the only residual is the transferred drug.
Device: Biolimus A9 Drug Coated Balloon
SELUTION SLR (Cordis / MedAlliance), a sirolimus-coated drug-coated balloon on a 0.014" rapid-exchange PTCA platform, CE-marked and used within its approved intended purpose.
Device: SELUTION SLR
Interventions in BioRISE arm aim to improve coronary luminal diameter for the treatment of de novo lesions well as lesions resulting from In-Stent Restenosis
The comparator applies to the de novo randomised cohort only; the single-arm ISR cohort has no comparator.
In-segment Late Lumen Loss (LLL) at 9 months
The primary endpoint is in-segment late lumen loss at 9 months, defined as the difference between the post-procedural minimal lumen diameter (MLD) and the 9-month follow-up MLD, measured by quantitative coronary angiography (QCA) and assessed by an blinded angiographic core laboratory (ARC-DCB Table 1, item 8). Analysis segment: in-segment, defined for this study as the balloon-treated segment plus 5 mm proximal and 5 mm distal, consistent with the comparator's pivotal trials (SELUTION DeNovo). ARC-DCB defines in-segment as the treated segment plus 1 mm, the ARC-DCB rationale for in-segment analysis (a proximal and distal buffer zone mitigating geographic miss= applies equally. The core laboratory additionally reports in-segment LLL with the ARC-DCB 1 mm margins.
Time frame: 9 months
Secondary outcomes
Device-Oriented Composite Endpoint (DOCE) at all time points Lesion-Oriented Composite Endpoint (LOCE) at 30 days Target Lesion Failure (TLF) at all timepoints Target Vessel Failure (TVF) at all timepoints Target-vessel MI (ARC-DCB) at all timepoints. All-cause mortality and cardiovascular death (per ARC-2 as adopted by ARC-DCB). Any myocardial infarction (Fourth and Fifth Universal Definition of Myocardial Infarction). Peri-procedural myocardial infarction (ARC-DCB) at discharge and 30 days. Any stroke (ischaemic, haemorrhagic or undetermined; Neuro-ARC) at all timepoints. Any defined lesion thrombosis. All TLR, TVR and non-TVR (ARC-DCB) at all timepoints. BARC 3-5 bleeding (BARC \[34\], as adopted by ARC-DCB) at discharge, 30 days and 1 year Binary restenosis (\> 50% diameter stenosis in the target segment at follow-up by QCA; ARC-DCB). Device success Procedural success
Time frame: • index procedure • Discharge up to 7 days (patient and hospital practice dependent) • 30 days • 9 months • 1 year • 2 years • 3 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Jan 2029, 22 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.